Cite
Schindler P, Grittner U, Oechtering J, et al. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neuroinflammation. 2021;18(1):105doi: 10.1186/s12974-021-02138-7.
Schindler, P., Grittner, U., Oechtering, J., Leppert, D., Siebert, N., Duchow, A. S., Oertel, F. C., Asseyer, S., Kuchling, J., Zimmermann, H. G., Brandt, A. U., Benkert, P., Reindl, M., Jarius, S., Paul, F., Bellmann-Strobl, J., Kuhle, J., & Ruprecht, K. (2021). Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Journal of neuroinflammation, 18(1), 105. https://doi.org/10.1186/s12974-021-02138-7
Schindler, Patrick, et al. "Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder." Journal of neuroinflammation vol. 18,1 (2021): 105. doi: https://doi.org/10.1186/s12974-021-02138-7
Schindler P, Grittner U, Oechtering J, Leppert D, Siebert N, Duchow AS, Oertel FC, Asseyer S, Kuchling J, Zimmermann HG, Brandt AU, Benkert P, Reindl M, Jarius S, Paul F, Bellmann-Strobl J, Kuhle J, Ruprecht K. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neuroinflammation. 2021 May 01;18(1):105. doi: 10.1186/s12974-021-02138-7. PMID: 33933106; PMCID: PMC8088712.
Copy
Download .nbib